Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | Phase 2 | terminated | May 24, 2011 | University of Oklahoma | The principal investigator terminated the study due to inactivity and low enrollment | Investigator |
| NCT02580422 | Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic… | — | terminated | Oct 20, 2015 | Indiana University | Low accrual | Enrollment / accrual |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With… | N/A | withdrawn | Jul 14, 2015 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | Phase 3 | terminated | Apr 22, 2014 | Incyte Corporation | The safety committee found no safety issues but recommended halting the study based on a lack of… | Safety / toxicity |
| NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced… | Phase 1 | terminated | Apr 2, 2013 | Incyte Corporation | Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014. | Other (stated, no rule matched) |
| NCT01851174 | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic… | Phase 2 | terminated | May 10, 2013 | Western Regional Medical Center | PI Leaving Site | Other (stated, no rule matched) |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | N/A | terminated | Nov 5, 2012 | Chinese University of Hong Kong | Poor recruitment | Enrollment / accrual |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced… | Phase 1 | terminated | Aug 28, 2013 | Incyte Corporation | Business decision. | Sponsor / business decision |
| NCT02494388 | Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions(CINE-Cyst) | — | terminated | Jul 10, 2015 | University of Medicine and Pharmacy Craiova | not stated | Not stated |
| NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With… | Phase 2 | terminated | Jan 24, 2007 | University of Iowa | Inadequate number of eligible patients | Other (stated, no rule matched) |
| NCT00262951 | Chemoradiation in Locally Advanced Pancreatic Cancer | Phase 2 | terminated | Dec 7, 2005 | Masonic Cancer Center, University of Minnesota | Closed at a planned interim analysis by meeting a predefined toxicity endpoint | Safety / toxicity |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase 1 | terminated | Nov 13, 2009 | Masonic Cancer Center, University of Minnesota | PI left institution. | Investigator |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | Phase 2 | terminated | Jan 26, 2010 | Masonic Cancer Center, University of Minnesota | Funding not available | Funding |
| NCT03001505 | Registry for Pancreatic Cancer | — | withdrawn | Dec 23, 2016 | Duke University | Study design changed to clinical database only with no research question to be studied. | Other (stated, no rule matched) |
| NCT00463840 | Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic… | Phase 1 / Phase 2 | terminated | Apr 20, 2007 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy… | Phase 2 | terminated | May 18, 2009 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT00753441 | Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the…(STENTBY) | N/A | terminated | Sep 16, 2008 | Heidelberg University | Low patient accrual | Enrollment / accrual |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | Phase 1 | withdrawn | Apr 8, 2014 | The University of Texas Medical Branch, Galveston | Study did not get funded. Study never started | Funding |
| NCT01688336 | FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2012 | UNC Lineberger Comprehensive Cancer Center | Results unlikely to impact treatment patterns. Time to complete not justified. | Other (stated, no rule matched) |
| NCT01768988 | Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized…(PANPAIN/1) | Phase 4 | terminated | Jan 16, 2013 | Parc de Salut Mar | Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to change… | Other (stated, no rule matched) |
| NCT01531712 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially… | Phase 2 | terminated | Feb 13, 2012 | Institut Català d'Oncologia | Due to a low recruitment rate since start of recruitment period. | Enrollment / accrual |
| NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and… | Phase 1 | terminated | Jan 11, 2016 | Verastem, Inc. | the company's decision to de-prioritize 4718 development | Sponsor / business decision |
| NCT02116322 | Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid… | N/A | terminated | Apr 16, 2014 | Johns Hopkins University | The study stopped as the used needle was difficult to maneuver in the corkscrew method being… | Other (stated, no rule matched) |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | Phase 1 | withdrawn | Jul 1, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01515046 | Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer(PACMAN-II) | Phase 2 | terminated | Jan 23, 2012 | Joseph J. Cullen | Standard of care changed to FOLFIRINOX; poor accrual. | Enrollment / accrual |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in… | Phase 2 | terminated | Feb 11, 2009 | University of Alabama at Birmingham | Sponsor stopped due to slow enrollment | Enrollment / accrual |
| NCT01940237 | A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients… | N/A | terminated | Sep 12, 2013 | New York State Psychiatric Institute | Low recruitment | Enrollment / accrual |
| NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients… | Phase 2 | terminated | Sep 17, 2014 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT00609765 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic… | Phase 2 | terminated | Feb 7, 2008 | H. Lee Moffitt Cancer Center and Research Institute | Development of new chemotherapy standard of care for treatment rendered the trial obsolete. | Other (stated, no rule matched) |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With… | Phase 1 / Phase 2 | terminated | May 22, 2009 | Cornerstone Pharmaceuticals | Suspended trial was not restarted. | Other (stated, no rule matched) |
| NCT01895790 | Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With… | Phase 1 / Phase 2 | withdrawn | Jul 11, 2013 | Johns Hopkins University | We could not find any candidate eligible for recruitment | Enrollment / accrual |
| NCT01108458 | A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | Phase 2 | terminated | Apr 22, 2010 | George Albert Fisher | Extreme toxicity of Pertuzumab and Erlotinib combination | Safety / toxicity |
| NCT00470535 | Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer | Phase 2 | terminated | May 7, 2007 | Roswell Park Cancer Institute | This study was terminated earlier due to a phase III study that showed this drug inferior to… | Other (stated, no rule matched) |
| NCT02242409 | Study of Gemcitabine and Abraxane for Pancreas Cancer | Phase 2 | terminated | Sep 17, 2014 | Georgetown University | Testing of combination no longer relevant | Other (stated, no rule matched) |
| NCT02366858 | Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During… | N/A | withdrawn | Feb 19, 2015 | AdventHealth | PI decision was made to discontinue the study | Other (stated, no rule matched) |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02446379 | Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery(CLIO) | — | withdrawn | May 18, 2015 | Lightpoint Medical Limited | Technology licensed to third party. Sponsor did not proceed with study. | Other (stated, no rule matched) |
| NCT01946646 | Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer(SR-GS) | Phase 1 | terminated | Sep 19, 2013 | National Taiwan University Hospital | slow recruitment | Enrollment / accrual |
| NCT01050426 | A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following…(PERU) | Phase 2 | terminated | Jan 15, 2010 | Royal Marsden NHS Foundation Trust | Data from other trials failed to demonstrate meaningful survival advantage | Other (stated, no rule matched) |
| NCT02851381 | Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable… | N/A | withdrawn | Aug 1, 2016 | Jonsson Comprehensive Cancer Center | The patient passed before treatment could be started | Other (stated, no rule matched) |
| NCT00726037 | A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in… | Phase 2 | terminated | Jul 31, 2008 | Loyola University | Collaborator withdrew support due to a drug supply interruption. | Drug supply |
| NCT01188109 | Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in… | Phase 2 | terminated | Aug 25, 2010 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00336700 | A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With… | Phase 2 | terminated | Jun 14, 2006 | Herbert J. Zeh, III MD, FACS | Study published November 2010 and no further work will be done | Other (stated, no rule matched) |
| NCT01104116 | Use of PET Imaging to Distinguish Malignant From Benign IPMN | N/A | terminated | Apr 15, 2010 | Columbia University | Poor enrollment; PI left the institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 2, 2018source: clinicaltrials